Clinical trials: Cancer: Solid Tumors
Malignant Solid Tumors
Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors
The purpose of this study is to evaluate the clinical safety and preliminary efficacy of MAGE-A4 TCR Gene-Modified T lymphocytes in the treatment of malignant solid tumor patients, such as malignant melanoma and lung cancer.
- Trial name
- NCT01694472
- Testing
- MAGE-A4 TCR Gene-Modified T Cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumors
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually…
- Trial name
- NCT01999972
- Testing
- axitinib, crizotinib
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Pfizer
Unspecified Adult Solid Tumor, Protocol Specific
Mistletoe Lectin in Treating Patients With Refractory Advanced Solid Tumors
RATIONALE: Mistletoe lectin may slow the growth of cancer cells and be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of mistletoe lectin in treating patients who have refractory…
- Trial name
- NCT00006477
- Testing
- mistletoe extract
- Where
- 2 sites in Germany, Norway
- Volunteers
- 26 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unspecified Childhood Solid Tumor, Protocol Specific
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more…
- Trial name
- NCT00673257
- Testing
- pharmacological study, dual x-ray absorptimetry
- Where
- 60 sites in United States, Australia and 2 more
- Volunteers
- 107 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Sarcoma
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as high-dose methotrexate work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00513981
- Testing
- leucovorin calcium, methotrexate, mass spectrometry
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Children's Cancer and Leukaemia Group
Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor…
- Conditions
- Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML, Refractory Pediatric AML
- Trial name
- NCT02638428
- Testing
- CancerSCAN™, Ifosfamide, Carboplatin
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Samsung Medical Center
Adult Solid Neoplasm
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
This phase I trial studies the side effects and best dose of tivantinib when given in combination with temsirolimus in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by…
- Trial name
- NCT01625156
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment and nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B16D1 in…
- Trial name
- NCT06475131
- Testing
- BL-B16D1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Advanced Cancer
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors.
- Trial name
- NCT03444753
- Testing
- BMS-986299, Nivolumab, Ipilimumab
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Adult
Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study
The study aims to retrospectively collect epidemiological and clinical data in patients with solid tumors and SARS Covid2 infections belonging to oncology centers within the Veneto Oncology Network
- Trial name
- NCT04811781
- Where
- 3 sites in Italy
- Volunteers
- 761 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
This is a multicenter, open label, phase I trial to evaluate the safety and tolerability, pharmacokinetic/ pharmacodynamic characteristics and to assess the preliminary efficacy of SIM0348 as monotherapy or with sintilimab in…
- Trial name
- NCT05718219
- Testing
- SIM0348, SIM0348 + Sintilimab
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Neoplasms
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573
The main objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose of HM95573.
- Trial name
- NCT02405065
- Testing
- HM95573
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Malignant Neoplasm, Solid Tumors
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
The purpose of this research study is to test the safety of chloroquine in combination with carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid tumors.
- Trial name
- NCT02071537
- Testing
- Chloroquine, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Cincinnati
Solid Cancers
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies.
- Trial name
- NCT02174172
- Testing
- Atezolizumab, Bevacizumab, Interferon alfa-2b
- Where
- 9 sites in United States, Netherlands
- Volunteers
- 158 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
The main purpose of this study is to test the safety of three study drugs, bevacizumab (Avastin™), Everolimus (Afinitor™) and LBH589 (Panobinostat) when they are given together.
- Trial name
- BEL (NCT01055795)
- Testing
- Bevacizumab, Everolimus and LBH589
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Herbert Hurwitz
Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
A Study of Oncobax®-AK in Patients With Advanced Solid Tumors
Akkermansia muciniphila is a naturally occurring bacterium found in the healthy human gastrointestinal tract. Analysis of the gut microbiota of NSCLC or RCC patients shows that the presence of Akkermansia is associated with the…
- Trial name
- NCT05865730
- Testing
- Live Bacterial Product - Akkermansia muciniphila
- Where
- 4 sites in Belgium, France
- Volunteers
- 122 people
- Sponsor
- EverImmune
Solid Tumor
A Study of RD14-01 in Patients With Advanced Solid Tumors
This study will evaluate the safety and tolerability of RD14-01, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ advanced solid tumors.
- Trial name
- NCT05638828
- Testing
- RD14-01 Cell injection
- Volunteers
- 24 people
- Sponsor
- Shen Lin
Select Advanced Solid Tumors
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME.
- Trial name
- NCT04262466
- Testing
- Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy
- Where
- 76 sites in United States, Australia and 15 more
- Volunteers
- 410 people
- Sponsor
- Immunocore Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.